The role of plasminogen-plasmin system in cancer
- PMID: 19377918
- DOI: 10.1007/978-0-387-79962-9_4
The role of plasminogen-plasmin system in cancer
Abstract
Components of the plasminogen-plasmin system participate in a wide variety of physiologic and pathologic processes, including tumor growth, invasion and metastasis, through their effect on angiogenesis and cell migration. These components are found in most tumors and their expression not only signifies their function but also carries a prognostic value. Their expression is in turn modulated by cytokines and growth factors, many of which are up-regulated in cancer. Though both tPA and uPA are expressed in tumor cells, uPA with its receptor (uPAR) is mostly involved in cellular functions, while tPA with its receptor Annexin II on endothelial surface, regulates intravascular fibrin deposition. Among the inhibitors of fibrinolysis, PAI-1 is a major player in the pathogenesis of many vascular diseases as well as in cancer. Therapeutic interventions, either using plasminogen activators or experimental inhibitor agents against PAI-1, have shown encouraging results in experimental tumors but not been verified clinically.
Similar articles
-
The plasminogen activator system and cancer.Pathophysiol Haemost Thromb. 2008;36(3-4):184-94. doi: 10.1159/000175156. Epub 2009 Jan 27. Pathophysiol Haemost Thromb. 2008. PMID: 19176991 Review.
-
Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression.Exp Mol Pathol. 2006 Oct;81(2):146-56. doi: 10.1016/j.yexmp.2006.03.003. Epub 2006 Apr 27. Exp Mol Pathol. 2006. PMID: 16643892
-
Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation.Exp Mol Pathol. 2010 Apr;88(2):278-86. doi: 10.1016/j.yexmp.2010.01.001. Epub 2010 Jan 15. Exp Mol Pathol. 2010. PMID: 20079732
-
Evolving role of uPA/uPAR system in human cancers.Cancer Treat Rev. 2008 Apr;34(2):122-36. doi: 10.1016/j.ctrv.2007.10.005. Epub 2007 Dec 26. Cancer Treat Rev. 2008. PMID: 18162327 Review.
-
Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S46-58. doi: 10.1097/01.blo.0000093845.72468.bd. Clin Orthop Relat Res. 2003. PMID: 14600592 Review.
Cited by
-
PAI-1 secretion of endometrial and endometriotic cells is Smad2/3- and ERK1/2-dependent and influences cell adhesion.Am J Transl Res. 2016 May 15;8(5):2394-402. eCollection 2016. Am J Transl Res. 2016. PMID: 27347347 Free PMC article.
-
Expression of the inhibitory Ly49E receptor is not critically involved in the immune response against cutaneous, pulmonary or liver tumours.Sci Rep. 2016 Jul 29;6:30564. doi: 10.1038/srep30564. Sci Rep. 2016. PMID: 27469529 Free PMC article.
-
Plasmin-Binding Tripeptide-Decorated Liposomes Loading Pyrazolo[3,4-d]pyrimidines for Targeting Hepatocellular Carcinoma.ACS Med Chem Lett. 2018 May 7;9(7):646-651. doi: 10.1021/acsmedchemlett.8b00062. eCollection 2018 Jul 12. ACS Med Chem Lett. 2018. PMID: 30034594 Free PMC article.
-
A novel mechanism of plasminogen activation in epithelial and mesenchymal cells.Sci Rep. 2018 Sep 20;8(1):14091. doi: 10.1038/s41598-018-32433-y. Sci Rep. 2018. PMID: 30237490 Free PMC article.
-
Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer.BMC Cancer. 2019 Jul 15;19(1):692. doi: 10.1186/s12885-019-5857-0. BMC Cancer. 2019. PMID: 31307406 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous